OncoZenge AB Stock

Equities

ONCOZ

SE0015504097

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:35 2024-04-26 EDT 5-day change 1st Jan Change
3.895 SEK +0.13% Intraday chart for OncoZenge AB -5.23% +26.05%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 45.62M 499M 62.36M
Net income 2024 * -8M -87.52M -10.94M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * 3M 32.82M 4.1M Net cash position 2025 * 3M 32.82M 4.1M EV / Sales 2025 * -
P/E ratio 2024 *
-5.73 x
P/E ratio 2025 *
-
Employees 2
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.13%
1 week-5.23%
Current month+14.56%
1 month+11.29%
3 months-48.61%
6 months+31.81%
Current year+26.05%
More quotes
1 week
3.72
Extreme 3.72
4.39
1 month
3.20
Extreme 3.2
4.50
Current year
2.80
Extreme 2.8
7.96
1 year
1.60
Extreme 1.6
10.56
3 years
1.60
Extreme 1.6
15.00
5 years
1.60
Extreme 1.6
17.60
10 years
1.60
Extreme 1.6
17.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-12
Director of Finance/CFO 68 23-10-11
Chief Tech/Sci/R&D Officer 72 21-04-30
Members of the board TitleAgeSince
Director/Board Member 38 23-09-08
More insiders
Date Price Change Volume
24-04-26 3.895 +0.13% 32,174
24-04-25 3.89 -9.43% 75,144
24-04-24 4.295 +6.18% 18,193
24-04-23 4.045 -3.80% 13,212
24-04-22 4.205 +2.31% 25,812

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am

More quotes
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.
Calendar
More about the company

Annual profits - Rate of surprise